Axinn Represents Thermo Fisher in $7.2 Billion Acquisition of Patheon
May 17, 2017
Axinn is representing Thermo Fisher Scientific Inc. in its $7.2 billion acquisition of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The Axinn team consists of John Harkrider and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
Wait, We Have To Tell Who? What You Need To Know About State Premerger Notifications
Podcast
MBK | MSK Fellowship Summit 2025
Sponsorship
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Attorneys Recognized by IAM Patent 1000
News
Intellectual Property
Intellectual Property and Antitrust
Byline Articles
Intellectual Property